Evidence map›Paper›PMID 28989889›Full record

ReviewIndian journal of endocrinology and metabolism

Sodium-glucose Cotransporter 2 Inhibitor Use: A Pharmaco-ergonomic Qualification Tool.

Sanjay Kalra, A G Unnikrishnan, Manash Baruah, Pallavi Kawatra, Jignesh Ved

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sanjay KalraDirector, Bharti Hospital and BRIDE, Karnal, Haryana, India.
A G UnnikrishnanDirector, Chellaram Diabetes Institute, Pune, Maharashtra, India.
Manash BaruahExcel Center (Initiative of Excelcare Hospitals Pvt. Ltd.), Guwahati, Assam, India.
Pallavi KawatraDepartment of Medical Affairs, Boehringer Ingelheim, Mumbai, Maharashtra, India.
Jignesh VedDepartment of Medical Affairs, Boehringer Ingelheim, Mumbai, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, based on a clinical score. This tool may serve as a simple and inexpensive practical guide, to optimize the risk-benefit considerations for SGLT2-i agents.

Indexed as

Pharmaco-ergonomicssodium-glucose cotransporter 2 inhibitor clinical scoresodium-glucose cotransporter 2 inhibitor qualification tool

Identifiers

PMID28989889
PMCPMC5628551

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.